Biohaven Pharmaceutical (NYSE:BHVN) PT Raised to $64.00 at Leerink Swann

Share on StockTwits

Biohaven Pharmaceutical (NYSE:BHVN) had its price objective boosted by analysts at Leerink Swann from $62.00 to $64.00 in a report issued on Friday, The Fly reports. The firm currently has an “outperform” rating on the stock. Leerink Swann’s target price points to a potential upside of 16.68% from the stock’s previous close.

A number of other brokerages have also recently issued reports on BHVN. Zacks Investment Research cut shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, October 21st. Cantor Fitzgerald raised their target price on Biohaven Pharmaceutical from $87.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, October 28th. ValuEngine cut Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Goldman Sachs Group set a $89.00 price target on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Finally, Morgan Stanley set a $50.00 price target on Biohaven Pharmaceutical and gave the stock a “hold” rating in a research note on Friday, August 9th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $71.42.

BHVN stock opened at $54.85 on Friday. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -8.92 and a beta of 0.46. Biohaven Pharmaceutical has a 12 month low of $29.17 and a 12 month high of $67.86. The firm has a 50 day moving average of $50.24 and a two-hundred day moving average of $47.00.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings results on Friday, November 1st. The company reported ($2.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.47). As a group, sell-side analysts expect that Biohaven Pharmaceutical will post -7.55 earnings per share for the current fiscal year.

In related news, insider Elyse Stock sold 17,700 shares of Biohaven Pharmaceutical stock in a transaction on Friday, October 18th. The shares were sold at an average price of $45.07, for a total value of $797,739.00. Following the transaction, the insider now owns 17,700 shares in the company, valued at approximately $797,739. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Eric Aguiar sold 1,250 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $55.24, for a total transaction of $69,050.00. Following the transaction, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $662,880. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,414 shares of company stock valued at $1,912,724. 23.90% of the stock is owned by insiders.

Large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in shares of Biohaven Pharmaceutical by 511.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock worth $46,000 after purchasing an additional 920 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in Biohaven Pharmaceutical in the 2nd quarter worth approximately $65,000. Aperio Group LLC bought a new position in Biohaven Pharmaceutical in the 2nd quarter worth approximately $71,000. Glen Harbor Capital Management LLC lifted its holdings in shares of Biohaven Pharmaceutical by 165.9% during the second quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after buying an additional 1,088 shares during the last quarter. Finally, Canton Hathaway LLC acquired a new position in shares of Biohaven Pharmaceutical during the third quarter worth approximately $83,000. 93.52% of the stock is currently owned by institutional investors.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Further Reading: What is a stock portfolio tracker?

The Fly

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.